Cancer: markers, syndromes Flashcards
CA 15-3 (cancer antigen)
Breast cancer: 75% of metastatic disease
Bowel cancer
Lung cancer
(Cirrhosis, hepatitis, benign breast disease)
CA19-9 (Cancer antigen)
Pancreatic cancer Bowel cancer Lung cancer Gall bladder cancer (Gallstones, pancreatitis, cystic fibrosis, liver disease)
CEA (carcinoembryonic antigen)
Bowel cancer
Lung, Breast, Liver, Pancreas, Stomach, Ovary cancer
(IBD, liver disease)
SMRP (soluble mesothelin-related peptide)
Malignant mesothelioma
Thyroglobulin
Thyroid cancer: Used to assess completeness of removal of thyroid in throidectomy and recurrence of disease
AFP (alpha-fetoprotein)
Hepatocellular carcinoma
Germ-cell tumours (Testicular)
(Cirrhosis, chronic hepatitis)
BCGR (B-cell immunoglobulin gene rearrangement)
B-cell lymphoma
BCR-ABL
Chronic myeloid leukaemia (CML)
Acute lymphoblastic leukaemia (ALL)
CA-125 (cancer antigen)
Ovarian cancer: 80%
Endometrial cancer
Lung, breast, GI cancers
(Pregnancy, menstruation, endometriosis, PID)
Calcitonin
Medullary thyroid cancer (and precursor C-cell hyperplasia)
Lung, breast and pancreatic cancer, Insulinomas, leukaemia
CgA (chromogranin A)
Carcinoid tumours
Phaeochromocytoma
(Liver disease, IBD, renal disease)
Gastrin
Gastrinoma (hyperplasia of gastrin-producing cells)
hCG (human chorionic gonadothropin)
Gestational trophoblastic disease
Germ cell tumours (testis/ovaries)
Choriocarcinoma
HER-2 (Human epidermal growth factor receptor-2)
Tested on breast tumour cells
25-30% positive
Associated with faster growth
Targeted treatment (e.g. trastuzumab)
Oestrogen and progesterone receptors
Assessed on breast cancer tissue
Oestrogen and progesterone positive cancer is likely to respond to anti-hormone treatments (e.g. tamoxifen)
Hereditary non-polyposis colorectal cancer (HNPCC): Lynch Syndrome
Gene: MSH2, MLH1, MSH6, PMS2
Autosomal dominant
Colon, endometrial, gastric, small intestine, urothelial
BRCA1
Hereditary breast-ovarian cancer syndrome: “King syndrome”
Tumour suppressor gene Autosomal dominant Breast cancer: 50-60% (males: 1.2%): triple negative Ovarian cancer: 40-65% Prostate: 9% Pancreas: 1-3%
BRCA2
Hereditary breast-ovarian cancer syndrome: “King syndrome”
Tumour suppressor gene Autosomal dominant Breast cancer: 40-55% (males: 9%) Ovarian: 15-25% Prostate: 15% Pancreas: 2-7%
Neurofibromatosis
Gene: NF1 Autosomal dominant Cancer: neurofibroma, nerve glioma, neurofibrosarcoma 8-12% lifetime risk Non-cancer Sx: MSK: spine abnormalities, myopathy Skin: cafe au lait, dermal neurofibroma Eye: Lisch nodules, optic nerve glioma
Familial retinoblastoma
Gene: RB1 Autosomal dominant Tumour suppressor gene Retinoblastoma Other primitive neuroectodermal tumours (PNETs)
Multiple endocrine neoplasia 1 (MEN1)
Autosomal dominant MEN1 gene: Tumour suppressor gene Pituitary adenoma Parathyroid hyperplasia Pancreatic tumours (insulinoma most common. Glucagonoma, gastrinoma)
Multiple endocrine neoplasia 2a (MEN2a)
"Simple syndrome" Autosomal dominant Parathyroid hyperplasia Medullary thyroid carcinoma Pheochromocytoma
Multiple endocrine neoplasia 2b (MEN2b)
Variations of RET proco-oncogenes Mucosal neuromas Marfanoid body habitus Medullary thyroid cancer Pheochromocytoma
Familial adenomatous polyposis (FAP)
Autosomal dominant APC gene: Tumour supressor gene Polyps (colorectal, duodenum) Colorectal cancer (7% by 21. 87% by 45. 93% by 50) Gardner fibroma Desmoid tumours Osteomata
Von Hippel-Lindau disease
Autosomal dominant VHL tumour suppressor gene Angiomatosis Haemoangioblastomas Pheochromocytoma Renal cell carcinoma {pancreatic cysts
Li-Fraumeni Syndrome
Autosomal dominant
TP53 gene mutation: tumour suppressor
Sarcoma, Breast, Leukaemia and Adrenal gland syndrome (SBLA syndrome)
Brain cancers, melanoma, colon, pancreas
Fanconi Anaemia
Autosomal recessive FA gene Myelodysplastic syndromes Acute myeloid leukaemia Bone marrow failure